ANAB: Rega marang dodolan AnaptysBio Inc
Risk minimization through the transfer of antibody rights to industry giants protects AnaptysBio, Inc. (ANAB) capital, which drives the price action. The current price-to-sales ratio demonstrates the impact of this strategy, where the 6.00 mark serves as the relevant indicator. Growth is fueled by Jemperli royalties to develop the immune pipeline, while revenues are based on partner payments and the treatment of skin pathologies.
Rincian metrik lan analitis perusahaan AnaptysBio Corp (ANAB)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal AnaptysBio, Inc.|ANAB - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas AnaptysBio Inc.|ANAB - Gunggung utang perusahaan|Utang marang modal buku AnaptysBio Corp|ANAB - Kewajiban jangka dawa perusahaan|Utang jangka cendhak AnaptysBio|Koefisien jangkoan perantara anaptysbio.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ANAB - Bathi resik|Bathi sing dikarepake AnaptysBio, Inc.|ANAB - Pangali P/E|Kapitalisasi marang proyeksi bathi AnaptysBio Inc|ANAB - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan AnaptysBio Corp|ANAB - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku AnaptysBio|ANAB - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan anaptysbio.com|ANAB - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep AnaptysBio, Inc.
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:anaptysbio.com
The P/S multiple determines the market value of one dollar of revenue, allowing for an assessment of the premium paid for a business relative to its actual sales. Analyzing the ratio of market capitalization to revenue helps identify whether AnaptysBio, Inc. (ANAB) quotes are overheated, which is critical when optimizing R&D expenses through external contractors who eliminate production risks but impact the final capitalization efficiency.
Karo sapa AnaptysBio, Inc. saingan
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX - Multiplikator P/S|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan KNSA|GRFS (Grifols) - Multiplikator P/S|Multiplikator P/S Adaptive Biotech|Rasio rega marang pendapatan Celldex (CLDX)|AUPH: Rasio rega marang dodolan|BioCryst - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan VERA (veratx.com)|DNTH: Kapitalisasi marang pendapatan|Rega marang dodolan Pharvaris NV|AbCellera Biologics Inc (ABCL) - Rasio rega marang pendapatan|TRML - Koefisien rega marang pendapatan|PGEN (Precigen, Inc.) - Multiplikator P/S|Rasio rega marang pendapatan PHAR|Multiplikator P/S NKTR|Koefisien rega marang pendapatan Upstream Bio, Inc.|Rasio rega marang pendapatan Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Rega marang dodolan|GOSS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan KALV (kalvista.com)|SEPN: Multiplikator P/S|PVLA - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Savara Corp|Rasio kapitalisasi marang pendapatan RIGL (Rigel Corp)|Multiplikator P/S ATXS|Kapitalisasi marang pendapatan engene.com ENGN|RAPT Therapeutics - Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Aerovate Therapeutics, Inc. (JBIO)|Aclaris - Multiplikator P/S|KYTX - Multiplikator P/S|Tiziana Life Sciences (TLSA) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CABA|VTYX (Ventyx Biosciences, Inc.) - Multiplikator P/S|Multiplikator P/S Theratechnologies, Inc.|Multiplikator P/S AVTX|Rasio rega marang pendapatan ELDN (Eledon Pharmaceuticals, Inc)|Rasio rega marang pendapatan Agenus AGEN|CLYM (climbbio.com) - Rasio rega marang dodolan|Zura Bio - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ATYR (aTyr Pharma Inc)|ADAG: Multiplikator P/S|Ikena Oncology (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Labs Inc|EQ: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Connect Biopharma (CNTB)|Kapitalisasi marang pendapatan immunic-therapeutics.com IMUX|Multiplikator P/S ATRA (Atara Bio)|Multiplikator P/S InflaRx NV IFRX|XFOR: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACET (Adicet Bio)|CELU: Multiplikator P/S|INMB - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Barinthus Bio|Kapitalisasi marang pendapatan Kezar Life Sciences Inc (KZR)|Rasio rega marang pendapatan SAB Biotherapeutics (SABS)|Kapitalisasi marang pendapatan akaritx.com AKTX|Enlivex Therapeutics Ltd. - Kapitalisasi marang pendapatan|Multiplikator P/S Q32 Bio Inc QTTB|GOVX - Rasio rega marang pendapatan|EDSA (Edesa Biotech Corp) - Rasio kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|Rega marang dodolan Carisma Therapeutics Inc. (CARM)|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|Multiplikator P/S Bolt Bio|Rasio rega marang pendapatan HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S AIM (AIM ImmunoTech Inc.)|Multiplikator P/S Aditxt Inc. ADTX|GRI - Rasio rega marang pendapatan|Rasio rega marang dodolan XRTX|HIND (ReShape Lifesciences) - Kapitalisasi marang pendapatan|REVB: Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan INDP|Rega marang dodolan scinai.com SCNI|Rasio rega marang pendapatan CalciMedica, Inc. (CALI)|Koefisien rega marang pendapatan affimed.com|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. - Rasio rega marang pendapatan|IGM Bio - Multiplikator P/S|Koefisien rega marang pendapatan iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rega marang dodolan TC BioPharm (Holdings) Plc (TCBP)|Kapitalisasi marang pendapatan THRD
